Published in Ann Surg Oncol on March 01, 2000
Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med (2014) 10.69
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
Melanoma genetics and the development of rational therapeutics. J Clin Invest (2005) 1.50
Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial. Lancet Oncol (2016) 1.45
Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol (2009) 1.18
Significance of sentinel lymph node biopsy in malignant melanoma: overview of international data. Int J Clin Oncol (2009) 1.15
Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann Surg (2002) 1.15
Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg (2008) 1.10
Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res (2010) 1.01
Anal melanoma. Clin Colon Rectal Surg (2006) 1.00
Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer Institute. J Surg Oncol (2010) 1.00
Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am (2011) 0.98
Surgical management of melanoma: an EORTC Melanoma Group survey. Ecancermedicalscience (2013) 0.93
Malignant melanoma of the skin: long-term follow-up and time to first recurrence. World J Surg (2011) 0.91
Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma. Clin Exp Metastasis (2012) 0.91
Melanoma in pediatric, adolescent, and young adult patients. Semin Oncol (2009) 0.89
Impact of Completion Lymph Node Dissection on Patients with Positive Sentinel Lymph Node Biopsy in Melanoma. J Am Coll Surg (2016) 0.88
Primary cutaneous melanoma of the breast: A case report. Cases J (2008) 0.85
Surgery and sentinel lymph node biopsy. Semin Oncol (2007) 0.85
Importance of tumor load in the sentinel node in melanoma: clinical dilemmas. Nat Rev Clin Oncol (2010) 0.84
How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)? Ann Surg Oncol (2008) 0.84
Lymphatic dysfunction attenuates tumor immunity through impaired antigen presentation. Oncotarget (2015) 0.83
Clinical utilities and biological characteristics of melanoma sentinel lymph nodes. World J Clin Oncol (2016) 0.82
Salvage surgery for a giant melanoma on the back. Rare Tumors (2011) 0.81
Treatment strategy for cutaneous malignant melanoma. Int J Clin Oncol (2005) 0.80
Malignant melanoma of the head and neck: a brief review of pathophysiology, current staging, and management. Ochsner J (2008) 0.80
Therapeutic effect of sentinel lymph node biopsy in melanoma remains an open question. J Clin Oncol (2009) 0.80
Sentinel lymph node biopsy for cutaneous melanoma: results of 10 years' experience in two regional training hospitals in the Netherlands. Int J Clin Oncol (2012) 0.79
Parametric modeling of localized melanoma prognosis and outcome. J Biopharm Stat (2009) 0.78
State of melanoma: an historic overview of a field in transition. Hematol Oncol Clin North Am (2014) 0.76
Melanoma characteristics in Brazil: demographics, treatment, and survival analysis. BMC Res Notes (2015) 0.76
One-day or two-day procedure for sentinel node biopsy in melanoma? Eur J Nucl Med Mol Imaging (2009) 0.75
Update and Review on the Surgical Management of Primary Cutaneous Melanoma. Healthcare (Basel) (2014) 0.75
Predictive factors for loco regional recurrence and distant metastasis following primary surgical treatment of cutaneous melanoma. Indian J Dermatol (2014) 0.75
Regional nodal surgery for melanoma impacts recurrence rates and survival. Ann Surg Oncol (2000) 0.75
Management of regional lymph node basins in melanoma. Ochsner J (2010) 0.75
Prognosis of patients with melanoma and microsatellitosis undergoing sentinel lymph node biopsy. Ann Surg Oncol (2013) 0.75
Intraoperative mapping of sentinel lymph node metastases using a clinically translated ultrasmall silica nanoparticle. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2015) 0.75
Emerging evidence for a survival benefit associated with regional lymph node dissection for melanoma. Ann Surg Oncol (2000) 0.75
Controversies in the diagnosis and treatment of early cutaneous melanoma. J Med Life (2015) 0.75
Sentinel lymph node biopsy in melanoma management: its significance and potential problems. Int J Clin Oncol (2009) 0.75
Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma. Mol Clin Oncol (2016) 0.75
The regional treatment of malignant melanoma has been resistant to conventional treatment logic. Ann Surg Oncol (2000) 0.75
Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis. Ann Surg Oncol (2016) 0.75
Multiple lymphatic basin drainage from cutaneous melanoma as a prognostic factor. World J Surg (2012) 0.75
The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res (1969) 13.27
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol (1999) 7.59
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer (1996) 4.46
Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol (1999) 3.74
Cooperative hernia study. Pain in the postrepair patient. Ann Surg (1996) 3.57
Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg (1999) 3.56
Younger women with breast carcinoma have a poorer prognosis than older women. Cancer (1996) 3.54
Malignant melanoma of the extremities: a clinicopathologic study using levels of invasion (microstage). Cancer (1975) 3.26
Screening for cutaneous melanoma by skin self-examination. J Natl Cancer Inst (1996) 3.23
Malignant peripheral nerve sheath tumors. A clinicopathologic study of 28 cases. Cancer (1993) 2.89
GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol (2000) 2.86
Acupressure and the prevention of nausea and vomiting after laparoscopy. Br J Anaesth (1999) 2.77
Role of the clotting system in cell-mediated hypersensitivity. I. Fibrin deposition in delayed skin reactions in man. J Exp Med (1973) 2.75
BINOCULAR VISION IN MINERS. Br J Ophthalmol (1948) 2.73
Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med (1978) 2.69
Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg (1996) 2.68
The classification of malignant melanoma and its histologic reporting. Cancer (1973) 2.67
Nonfamilial cutaneous melanoma incidence in women associated with sun exposure before 20 years of age. Pediatrics (1989) 2.61
Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. Gut (2008) 2.51
Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol (1999) 2.50
Xanthine oxidoreductase catalyses the reduction of nitrates and nitrite to nitric oxide under hypoxic conditions. FEBS Lett (1998) 2.49
Recommendations for sentinel lymph node processing in breast cancer. Am J Surg Pathol (2002) 2.42
Common and uncommon melanocytic nevi and borderline melanomas. Semin Oncol (1975) 2.36
Melanoma in children. N Engl J Med (1995) 2.35
Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol (1997) 2.32
Benign cutaneous adnexal tumors with combined folliculosebaceous, apocrine, and eccrine differentiation. Clinicopathologic and immunohistochemical study of eight cases. Am J Dermatopathol (1996) 2.30
Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med (1987) 2.20
Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol (2001) 2.19
A factual, not arbitrary, basis for choice of resection margins in melanoma. Arch Dermatol (1996) 2.12
Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg (1993) 2.08
Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol (2001) 2.06
Giant condyloma acuminatum (Buschke-Lowenstein tumor) of the anorectal and perianal regions. Analysis of 42 cases. Dis Colon Rectum (1994) 2.04
Cryosurgery for malignant tumours of the liver. Can J Surg (1996) 2.04
Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol (2001) 2.03
The natural history of appendicitis in adults. A prospective study. Ann Surg (1995) 2.02
Reliability of the histopathologic diagnosis of melanocytic dysplasia. The Dysplastic Nevus Panel. Arch Dermatol (1997) 2.02
Pollination biology in a lowland dipterocarp forest inSarawak, Malaysia. I. Characteristics of the plant-pollinator communityin a lowland dipterocarp forest. Am J Bot (1998) 2.00
Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. Antimicrob Agents Chemother (1994) 1.98
Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. Nat Genet (1999) 1.93
Reduction of nitrite to nitric oxide catalyzed by xanthine oxidoreductase. J Biol Chem (2000) 1.93
Kimura's disease and angiolymphoid hyperplasia with eosinophilia: two distinct histopathological entities. J Cutan Pathol (1987) 1.92
Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol (1998) 1.92
Presentation, treatment, and outcome of local recurrence afterskin-sparing mastectomy and immediate breast reconstruction. Ann Surg Oncol (1999) 1.92
Automatic differentiation of melanoma from melanocytic nevi with multispectral digital dermoscopy: a feasibility study. J Am Acad Dermatol (2001) 1.91
A quantitative model of invasive Pseudomonas infection in burn injury. J Burn Care Rehabil (1994) 1.91
The nature of immune complexes in human cancer sera. J Immunol (1977) 1.88
A rational approach to the surgical management of melanoma. Ann Surg (1977) 1.88
The effect of surgical wounding on tumour development. Eur J Surg Oncol (1999) 1.88
Conventional TRAM flap versus free microsurgical TRAM flap for immediate breast reconstruction. Plast Reconstr Surg (1989) 1.87
Nonepidermal origin of malignant melanoma associated with a giant congenital nevocellular nevus. Plast Reconstr Surg (1981) 1.86
Dermal dendritic melanocytic proliferations: an update. Histopathology (2004) 1.84
Narrower margins for clinical stage I malignant melanoma. N Engl J Med (1982) 1.82
Primary melanoma of the skin: recognition and management. J Am Acad Dermatol (1980) 1.82
Mortality rates in patients with Barrett's oesophagus. Aliment Pharmacol Ther (2007) 1.81
Dehydration of a phosphonate substrate analogue by glycerol 3-phosphate dehydrogenase. Biochem J (1974) 1.80
A new immunologic marker for human Langerhans cells. N Engl J Med (1981) 1.79
Proceedings: Treatment of minimal breast cancer. Cancer (1974) 1.78
Anorectal melanoma. Cancer (1981) 1.77
Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am (1998) 1.77
Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions. J Am Coll Surg (1996) 1.77
A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol (2001) 1.77
Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol (1981) 1.76
Basophilic leukocytes in allergic contact dermatitis. J Exp Med (1972) 1.75
Rejection of first-set skin allografts in man. the microvasculature is the critical target of the immune response. J Exp Med (1979) 1.74
Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis. Br J Obstet Gynaecol (1992) 1.74
Characterization of Langerhans cells by the use of monoclonal antibodies. Lab Invest (1981) 1.73
Prognostic factors for melanoma patients with lesions 0.76 - 1.69 mm in thickness. An appraisal of "thin" level IV lesions. Ann Surg (1982) 1.72
Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol (2000) 1.71
Spitz tumors in children: a grading system for risk stratification. Arch Dermatol (1999) 1.71
Dysplastic melanocytic nevi: a reproducible histologic definition emphasizing cellular morphology. Mod Pathol (1989) 1.71
Pilomatrix carcinoma or calcifying epitheliocarcinoma of Malherbe: a case report and review of literature. Cancer (1980) 1.70
The chest roentgenogram in cystic fibrosis: a new scoring system. Pediatrics (1979) 1.70
Morphology of delayed-type hypersensitivity reactions in man. II. Ultrastructural alterations affecting the microvasculature and the tissue mast cells. Lab Invest (1976) 1.70
Morphology of delayed type hypersensitivity reactions in man. I. Quantitative description of the inflammatory response. Lab Invest (1974) 1.68
Lentigo maligna and lentigo-maligna melanoma. Am J Pathol (1969) 1.68
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol (1994) 1.67
Squamoid eccrine ductal carcinoma. Histopathology (1997) 1.67
Metastatic patterns in soft-tissue sarcomas. Arch Surg (1983) 1.66